DE60202134T2 - Zyklische guanosine 3',5'-monophosphate phosphodiesterase inhibitoren - Google Patents

Zyklische guanosine 3',5'-monophosphate phosphodiesterase inhibitoren Download PDF

Info

Publication number
DE60202134T2
DE60202134T2 DE60202134T DE60202134T DE60202134T2 DE 60202134 T2 DE60202134 T2 DE 60202134T2 DE 60202134 T DE60202134 T DE 60202134T DE 60202134 T DE60202134 T DE 60202134T DE 60202134 T2 DE60202134 T2 DE 60202134T2
Authority
DE
Germany
Prior art keywords
alkyl
het
ethyl
preparation
methylsulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60202134T
Other languages
German (de)
English (en)
Other versions
DE60202134D1 (en
Inventor
Stephen M. Sandwich DENTON
Mark I. Sandwich KEMP
Sandra D. Sandwich NEWMAN
David J. Sandwich RAWSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of DE60202134D1 publication Critical patent/DE60202134D1/de
Application granted granted Critical
Publication of DE60202134T2 publication Critical patent/DE60202134T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60202134T 2001-03-16 2002-03-04 Zyklische guanosine 3',5'-monophosphate phosphodiesterase inhibitoren Expired - Fee Related DE60202134T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0106661.2A GB0106661D0 (en) 2001-03-16 2001-03-16 Pharmaceutically active compounds
GB0106661 2001-03-16
PCT/IB2002/000659 WO2002074774A1 (en) 2001-03-16 2002-03-04 Cyclic guanosine 3',5'-monophosphate phosphodiesterase inhibitors

Publications (2)

Publication Number Publication Date
DE60202134D1 DE60202134D1 (en) 2005-01-05
DE60202134T2 true DE60202134T2 (de) 2005-11-24

Family

ID=9910932

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60202134T Expired - Fee Related DE60202134T2 (de) 2001-03-16 2002-03-04 Zyklische guanosine 3',5'-monophosphate phosphodiesterase inhibitoren

Country Status (10)

Country Link
EP (1) EP1368352B1 (enExample)
JP (1) JP2004523585A (enExample)
AT (1) ATE283856T1 (enExample)
BR (1) BR0208154A (enExample)
CA (1) CA2439528A1 (enExample)
DE (1) DE60202134T2 (enExample)
ES (1) ES2231667T3 (enExample)
GB (1) GB0106661D0 (enExample)
MX (1) MXPA03005937A (enExample)
WO (1) WO2002074774A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE478872T1 (de) * 2002-03-28 2010-09-15 Ustav Ex Botan Av Cr V V I I O Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
PT1572173E (pt) 2002-12-13 2010-05-10 Warner Lambert Co Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
CN100374441C (zh) * 2003-06-06 2008-03-12 天津倍方科技发展有限公司 二氢吡咯[2，3-d]嘧啶-4-酮衍生物，其制备方法及其制药用途
JP2006219374A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
EP2256106B1 (en) 2003-07-22 2015-05-06 Astex Therapeutics Limited 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
AU2004274403A1 (en) * 2003-09-03 2005-03-31 Aventis Pharmaceuticals Inc. 5-aryl-Pyrazolo(4,3-d)pyrimidines, pyridines, and pyrazines and related compounds
US7485637B2 (en) 2005-01-04 2009-02-03 Hoffmann-La Roche Inc. Benzoyl-tetrahydropiperidine derivatives
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
WO2006082001A1 (en) 2005-02-07 2006-08-10 F.Hoffmann-La Roche Ag Heterocyclic substituted phenyl methanones as inhibitors of the glycine transporter 1
BRPI0608381A2 (pt) * 2005-02-18 2009-12-29 Surface Logix Inc compostos aprimorados farmacocineticamente
AU2006315436A1 (en) 2005-11-15 2007-05-24 Vertex Pharmaceuticals Incorporated Azaindazoles useful as inhibitors of kinases
ATE464289T1 (de) * 2005-11-16 2010-04-15 Hoffmann La Roche Neues verfahren zur herstellung von thoc
US8071765B2 (en) * 2006-12-21 2011-12-06 Topharman Shanghai Co., Ltd. Process for the preparation of sildenafil and intermediates thereof
KR20100016270A (ko) * 2007-05-11 2010-02-12 산텐 세이야꾸 가부시키가이샤 비맥각계의 선택적 ｄ2 수용체 작용제를 유효 성분으로서 함유하는 후안부 질환의 예방 또는 치료제
US8648085B2 (en) 2007-11-30 2014-02-11 Boehringer Ingelheim International Gmbh 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
CN102143965A (zh) 2008-09-08 2011-08-03 贝林格尔.英格海姆国际有限公司 吡唑并嘧啶酮及其在治疗中枢神经系统疾病中的用途
JP2012513464A (ja) 2008-12-23 2012-06-14 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク ホスホジエステラーゼ阻害剤及びその使用
UY32531A (es) 2009-03-31 2010-10-29 Boehringer Ingelheim Int Nuevos compuestos para el tratamiento de trastornos del snc
TWI393578B (zh) 2009-07-07 2013-04-21 瑞健集團股份有限公司 注射裝置
BR112013003097B1 (pt) 2010-08-12 2021-03-16 Boehringer Ingelheim International Gmbh 6-cicloalquil-pirazolopirimidinonas e composição farmacêutica
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
TWI557121B (zh) 2011-04-21 2016-11-11 原真股份有限公司 新穎激酶抑制劑
AU2012244550C1 (en) * 2011-04-21 2017-06-22 Origenis Gmbh Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors
CN104302640A (zh) 2012-03-16 2015-01-21 埃克希金医药品有限公司 3,5-二氨基吡唑激酶抑制剂
WO2014060113A1 (en) 2012-10-19 2014-04-24 Origenis Gmbh Novel kinase inhibitors
WO2014060112A1 (en) 2012-10-19 2014-04-24 Origenis Gmbh Pyrazolo[4,3-d]pyrimidines as kinase inhibitors
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
CN106029647A (zh) * 2013-12-20 2016-10-12 拜耳制药股份公司 葡萄糖转运抑制剂
MY191736A (en) 2014-12-23 2022-07-13 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
KR102862562B1 (ko) 2015-11-16 2025-09-19 토파두르 파마 아게 포스포디에스테라제 억제제로서 2-페닐-3,4-디하이드로피롤로[2,1-f][1,2,4]트리아지논 유도체 및 이의 용도
CN105669680B (zh) * 2016-03-24 2018-02-23 南京药捷安康生物科技有限公司 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂
JP2025513455A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1493685A (en) * 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
US6225315B1 (en) * 1998-11-30 2001-05-01 Pfizer Inc Method of treating nitrate-induced tolerance
HK1049834A1 (zh) * 1999-10-11 2003-05-30 辉瑞大药厂 用作磷酸二酯酶抑制剂的5-(2-取代的-5-杂环基磺酰基吡啶-3-基)-二氢吡唑并[4，3-d]嘧啶-7-酮类化合物

Also Published As

Publication number Publication date
ES2231667T3 (es) 2005-05-16
JP2004523585A (ja) 2004-08-05
ATE283856T1 (de) 2004-12-15
CA2439528A1 (en) 2002-09-26
GB0106661D0 (en) 2001-05-09
DE60202134D1 (en) 2005-01-05
MXPA03005937A (es) 2003-09-10
EP1368352A1 (en) 2003-12-10
BR0208154A (pt) 2004-03-02
WO2002074774A1 (en) 2002-09-26
EP1368352B1 (en) 2004-12-01

Similar Documents

Publication Publication Date Title
DE60204760T2 (de) Pyrazolo[4,3-d]pyrimidinon-verbindungen als cgmp pde-inhibitoren
DE60016615T2 (de) Pyrazolo[4,3-d]pyrimidinderivate
ES2231667T3 (es) Inhibidores de la 3',5'-monofosfato de guanosina ciclico fosfodiesterasa.
DE60002969T2 (de) Imidazo[5,1-f][1,2,4]triazinderivate
US6770645B2 (en) Pharmaceutically active compounds
DE69911448T2 (de) Pyrazolopyrimidinone, cgmp pde5 inhibitoren, zur behandlung von sexuellen funktionsstörungen
SK4562002A3 (en) 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)- dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors
US20020198223A1 (en) Pharmaceutically active compounds
DE602004012146T2 (de) Pyrazolopyrimidine
JP2004528320A (ja) 医薬活性化合物
US20020193388A1 (en) Pharmaceutically active compounds
US6794387B2 (en) Pharmaceutically active compounds
EP1380293A1 (en) Bone metabolism improving agents
DE60010914T2 (de) Wasserfreie salze
SK572003A3 (en) Crystalline therapeutic agent
HK1078574B (en) Pyrazolo [4,3-d] pyrimidine derivatives
HK1069577B (en) Pyrazolo [4,3-d] pyrimidine derivatives

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee